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Summary 
The physiology of the gastrointestinal tract presents serious barriers and challenges to oral 
drug delivery. The wide intra- and intersubject variability of gastrointestinal transit time is an 
important factor that can have a significant influence on drug bioavailability. Mucoadhesive 
formulations can increase and harmonize the passage time through the gastrointestinal tract, 
with the potential benefit of more reproducible drug bioavailability. This effect can be 
enhanced by using multiparticulate drug delivery system instead of single-unit dosage forms 
as the gastrointestinal transit of the formers is more reproducible and predictable. Delivery of 
such mucoadhesive multiparticulates to the colon can be of great benefit for local treatment of 
colonic diseases, such as Clostridium difficile infections, inflammatory bowel diseases (IBD) 
and colon cancer. However, so far no in vivo data on the usefulness of oral mucoadhesive 
formulations in the human proximal colon are available. Therefore, the aim of the work 
presented in this thesis was to develop a novel formulation platform for delivery of 
mucoadhesive multiparticulates to the colon for the treatment of Clostridium difficile 
infections. In the scope of the overall project a a proof-of-concept Phase 1 study was aimed 
therefore a formulation and manufacturing method based on standardized pharmaceutical 
processes was envisaged. 
Functionalized calcium carbonate (FCC, Omyapharm) porous microcarriers were selected as 
an alternative size range to nanoparticles and pellets. Drug loading of various substances into 
FCC was carried out on the principle of solvent evaporation and crystallization. The rotary-
evaporation and fluidized-bed processes were feasible to achieve high drug loads up to 40% 
(w/w). Loaded metronidazole benzoate (MBZ) and nifedipine as model drugs for poor 
aqueous solubility showed increased dissolution rates compared to drug crystals due to 
enlarged surface area of the loaded drug onto the FCC particles. 
Mucoadhesive coating of drug-loaded FCC microparticles was achieved with the cationic 
polymer chitosan using either a pH-dependent precipitation method, or a spray-coating method 
in the fluidized-bed process. To test the chitosan-coated microparticles for mucoadhesivity, an 
in vitro method to measure particle retention on porcine colonic mucosa (as model of the 
human colonic mucosa) was developed. This included the design of a flow-channel device and 
the validation of marker-ion analysis for quantification of detached microparticles.  
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Optimized formulations containing MBZ as model drug for local treatment of colonic diseases 
(Clostridium difficile infections) prepared using the fluidized-bed process, resulted in good in 
vitro particle retention. To serve as control, non-mucoadhesive microparticles containing 
ethylcellulose were developed. These mucoadhesive and non-mucoadhesive microparticles 
filled into colonic-targeted hard-shell capsules (Tillotts Pharma innovation, outside the scope 
of the thesis) will be used in a gamma scintigraphy study for a proof-of-concept of 
mucoadhesion in the human colon as a strategy to increase residence time.  
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1 Introduction 
1.1 Drug delivery via the oral route 
Oral intake of a medicine is the most convenient way of drug administration, and the 
development of an oral dosage form should be the primary goal to ensure a high patient 
compliance [1]. The small intestine with its enlarged surface area by microvilli still presents 
the preferred site of drug absorption, but not all drugs are suited for oral administration due to 
issues of absorption, metabolism, or stability in the gastrointestinal tract potentially resulting 
in insufficient bioavailability of the drug [2].  
The formulation of poorly water-soluble drugs still presents one of the major challenges in 
pharmaceutical development. Such drugs are prone to dissolve incompletely in the limited 
volume of intestinal fluids. The solubility-limited drug concentrations in the intestinal lumen 
can lead to low absorption rates, leading to an overall low bioavailability. Especially, class II 
and IV drugs of the Biopharmaceutics Classification System (BCS), the latter which are 
additionally characterized by low permeability through the endothelial membranes, require 
special formulation strategies. For example solid dispersions [3], lipid formulations [4], or 
carrier-based formulations in the nano- and microscale can help to reach temporarily increased 
drug concentrations [5]. The high intra- and interindividual variability of intestinal motility 
and gastrointestinal residence time presents a serious challenge regarding drug absorption 
conformity [6]. Mucoadhesive drug delivery systems have gained a lot of attention in the last 
two decades due to the potential to increase and harmonize gastrointestinal transit time and 
therefore improve overall drug bioavailability [7]. 
Local treatment of diseases related to the gastrointestinal tract presents a special application in 
oral drug delivery. The rationale is to deliver the drug directly to the site of action without 
being absorbed (or with reduced absorption) and distributed systemically via the blood stream. 
For example, gastro-retentive drug delivery systems were developed to eradicate Helicobacter 
pylori in the stomach [8,9]. A lot of effort has been undertaken to enable local therapy in the 
large intestine, and as a result, various coating technologies which dissolve or disintegrate in 
the distal small intestine or proximal colon have been developed and several medical products 
are in the market (e.g. Asacol®, Salofalk®, Ipocol®, Entocort®, and Budenofalk®) 
The combination of mucoadhesive and colonic-delivery strategies has great potential to 
improve the efficacy in treatment of colonic diseases such as inflammatory bowel diseases 
(IBD), Clostridium difficile infections, and colon cancer. and serve as well for systemic 
absorption of drugs which are extensively metabolized in the proximal small intestine (e.g. 
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peptides) [7,10] or which are substrate to efflux transporters having lower expression levels in 
the colon than in the jejunum and ileum [11].. However, this combinatory approach requires 
more research. To cover the scope of this project, a theoretical background on mucoadhesion 
and colonic drug delivery is given in this introductory Chapter 1.  
1.2 Mucoadhesion 
Bioadhesion can be defined as the binding of two materials for an extended period of time, 
provided that at least one of the materials is of biological nature. In terms of drug delivery, 
mucoadhesion explicitly describes the attachment of a drug carrier system to the mucus 
layer[12]. The high interest in mucoadhesive formulations is not only due to increased 
residence timewithin a particular region of the gut, but also due to the potential for systemic 
drug delivery via other mucosal membranes by allowing an intimate contact with the mucosa, 
such as buccal and nasal mucosa, circumventing the first-pass effect and allowing a more 
precise dosing [13,14]. The pioneer work of Nagai et al. [15,16] included the development of 
a nasal insulin delivery system, which showed remarkable bioavailability in beagle dogs, and 
definitively demonstrated the great potential of mucoadhesive dosage forms. The development 
of mucoadhesive formulations could also optimize localized therapy of diseases related to the 
mucosal membranes, since the drug carrier can be brought into close contact with the diseased 
tissue. Most marketed products are buccal and vaginal drug delivery systems as they have the 
advantage of direct accessibility at the site of administration [17]. For example, Buccastem® 
is a buccal bioadhesive tablet containing prochlorperazine maleate against nausea [18], and 
many bioadhesives vaginal gels containing the contraceptive drug nonoxynol-9 (spermicide) 
are available in the US and Canada. However, so far no clinical trials have been performed to 
investigate mucoadhesion in the human large intestine after oral-administration of colonic 
drug delivery systems. This Chapter 1.2 outlines the challenging aspects of mucoadhesion in 
the gastrointestinal tract. 
1.2.1 The gastrointestinal mucus layer 
The function of the mucosal membrane is to protect the underlying epithelial cells and 
maintain them under moist conditions. The role of the gastrointestinal mucus is rather delicate, 
as it must be permeable enough for nutrition purposes, and at the same time allowing an 
efficient protection against mechanical damage during digestion of food due to the viscoelastic 
properties of the hydrated mucin molecules acting as a lubricant [19]. The mucus layer 
provides a stable micro-pH environment via bicarbonate secretion and also acts as an effective 
diffusion barrier between the lumen and the epithelial cells to protect it against chemical 
degradation from gastric pH, digestive enzymes, and xenobiotics [20–22]. The mucus layer is 
also an effective diffusion barrier against bacteria and other pathogens, and the impairment of 
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the mucus layer is an important pathological cause for inflammation [23]. Since the large 
intestine shows the highest colonization density of bacteria [24], chronic inflammations of the 
colon (colitis) have higher prevalence compared to inflammations in other sections of the 
gastrointestinal tract [25]. A total of 1014 bacteria are estimated to be in the human gut (1011 
per gram of feces) [23]. To put this into context, our body consists of 1013 human cells [26]. 
Johannson et al. [27] showed evidence that the mucus layer is built up by a firmly attached 
inner mucus layer and a loose outer layer. It was observed that only the outer mucus layer is 
colonized, whereas the inner layer is impervious to the normal bacterial flora [28]. Due to the 
dynamic balance between mucus secretion and erosion, the mucus layer is constantly renewed, 
and the time required for complete renewal of the mucus layer is defined as the mucus 
turnover rate. Mucus turnover rate in rats was estimated in vivo using an invasive method 
inapplicable to humans [29]. The authors suggested that mucus turnover rate in humans might 
be close to the five hours measured in rats, and that the residence time of mucoadhesive 
dosage forms is then limited to the mucus gel turnover. 
Mucus thickness plays a governing role in terms of mucoadhesivity [30], but literature 
reportinghuman gastrointestinal mucus thickness is contradictory and diverges among the 
different in vitro and in vivo measurement methods. The modified staining of cryostat cross-
sections is superior to other in vitro methods, since the physiological conditions of the mucus 
are maintained [31,32]. Mucus thickness was measured in the stomach (144 ± 52 µm), small 
intestine (15.5 µm, no S.D.), cecum (23.1 ± 16 µm), transverse colon (31.2 ± 29 µm), and 
distal colon (45.7 ± 38 µm). Atuma et al. [33] reported an in vivo method for the determination 
of mucus thickness in rats, taking into account the presence of the two different adherent 
mucus layers. In contradiction to previous studies, mucus thickness was found to be highest in 
the colon. The loose mucus layer had a thickness of 714 ± 109 µm, and the firmly adherent 
mucus layer was 116 ± 51 µm in thickness. These findings could be extrapolated to humans, 
suggesting that the thickness of the mucus layer is higher in humans than in rats. In summary, 
mucus thickness in the human gastrointestinal tract ranges between 15 – 800 µm. However, a 
strong variation has to be considered between different gastrointestinal sections, individuals, 
and measurement methods. Especially in a diseased state of thegastrointestinal tract, such as 
ulcerative colitis and Crohn’s disease, the mucus thickness was found to vary significantly 
[34].  
To understand the mechanisms of mucoadhesion, it is important to know the chemical and 
structural composition of the mucus layers. Besides lipids and inorganic salts, the mucins are 
the key components of the mucus, which can bind up to 95% of water. [19,35]. Mucins are 
high-molecular-weight glycoproteins (0.5-40 x 106 Da). They are composed of a protein core 
with attached oligosaccharide branches (2-20 sugar residues). A schematic presentation of a 
mucin glycoprotein is shown in Fig. 1.1. The sugar residues of the oligosaccharide branches 
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are composed of galactose, fucose, N-acetylglucosamine, N-acetylgalactosamine, or 
N-acetylneuraminic acid [35,36]. The sugar residues are attached to distinct amino acids of the 
protein core controlled by different glycosyltransferase enzymes in the goblet cells [37]. The 
main bonding types are the N-linked (on asparagine) and O-linked glycosylation (on serine 
and threonine), from which the latter is more abundant in the human gastrointestinal mucus 
layer. Depending on the expression level of the core protein (i.e. MUC-1, MUC-2, MUC-3, 
MUC-13) and glycosyltransferases, different glycosylation products are obtained, resulting in 
a characteristic glycosylation pattern along the gastrointestinal tract [38]. Important functional 
groups are the sialic acids and the sulphonate esters, giving an overall negative charge to the 
intestinal mucus layer [35]. However, the presence of poly-O-acetylated sialic acid in colonic 
mucins gives these molecules a hydrophobic character and resistance to bacterial enzymatic 
degradation [39,40]. Intramolecular crosslinking of mucins by disulfide bridges builds up the 
flat and sheet-like mucin network and the interactions with transmembrane mucins are 
important for the firmly attached inner mucus layer [41]. At the same time, the creation of 
large networks makes the mucin insoluble in water and enhances the viscoelastic properties of 
the outer mucus gel layer [42]. 
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Fig. 1.1: Schematic structure of mucin (adapted from [43]) 
 
1.2.2 Mucoadhesive polymers 
Most of the excipients used for mucoadhesive functionalization of a dosage form are of a 
polymeric nature. They usually have hydrophilic functional groups, e.g. carboxylic acids, 
enabling the formation of H-bonds with the mucin molecules. Examples of COOH-rich 
polymers with good mucoadhesive properties are poly acrylic acids (Carbopol®) or 
carboxymethyl cellulose [44]. Other cellulose derivatives such as ethylhydroxyethyl cellulose 
[45], hydroxypropylmethyl cellulose and hydroxypropyl cellulose [46] were also reported to 
be mucoadhesive.  
One of the most investigated polymers with excellent mucoadhesive properties is chitosan 
[47–50], a biodegradable and biocompatible cationic amino polysaccharide obtained by partial 
deacetylation of chitin [51]. The mechanisms involved in the mucoadhesion of chitosan were 
elucidated by Sogias et al. [52] in a systematic study by “switching off” the contributing 
functional groups and investigating their influence on adhesive interactions. The authors 
concluded that the attractive interactions between chitosan and mucin are based on multiple 
adhesive mechanisms, such as electrostatic attraction, hydrogen bonding, and hydrophobic 
effects, with a major contribution from electrostatic interactions due to the cationic nature of 
chitosan.  
Recent advances in mucoadhesive materials led to a second generation of bioadhesives. For 
example, thiolated polymers, the so called “thiomers”, can make covalent disulfide bonds with 
cysteines which are components of the mucin protein core [53]. Therefore, thiomers can target 
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the mucus layer with high binding strength. The intellectual property of thiomer innovations 
belong to the start-up company ThioMatrix GmbH.  
Lectins are proteins or glycoproteins and also belong to the second generation of bioadhesives. 
They recognize the receptor-like structures of the cell membranes and bind with high 
specificity (cytoadhesion). Since lectins do not bind to the mucus layer, they were suggested to 
present an effective strategy to increase the residence time on mucosal tissues without being 
affected by the mucus turnover [54].  
1.2.3 Theories of mucoadhesion 
Mucoadhesion is a complex physicochemical process and more than one mechanism is 
involved. A number of general theories from surface science describing the phenomenon of 
adhesion were adapted to explain the mechanisms of mucoadhesion, namely the adsorption 
theory, electronic theory, wetting theory, diffusion theory, mechanical theory, and the fracture 
theory, which were well described elsewhere [55]. 
Adhesive interactions based on the adsorption theory are considered to be the major 
contribution to mucoadhesion. It describes the attraction between the mucins and 
mucoadhesive polymers on the basis of specific molecular interactions such as ionic bonding, 
hydrogen bonding, and van der Waals’ forces. Hydrophobic effects can occur when the 
mucoadhesive polymers have an amphiphilic nature. Non-covalent and non-ionic bonds are in 
general low, but the net result leads to a strong interaction between mucins and polymers. 
Electrostatic forces are important for cationic polymers, such as chitosan, due to the ionic 
interactions with the negatively charged mucins. The chemisorption theory is a subsection of 
the adsorption theory, and includes the creation of strong covalent bonds as in case of 
thiomers.  
 
In reality, it is impossible to determine the contributions of different adhesive mechanisms to 
the overall adhesive strength. Mucoadhesion can be described as a process of consecutive 
steps which are based on different mechanisms [12,55] as shown in Fig. 1.2. In a first phase 
(contact stage), the dosage form binds water molecules and swells (wetting theory) facilitating 
intimate contact with the mucosa. In a second phase (consolidation stage), non-covalent bonds 
are created (electronic and adsorption theory) and polymer chains interpenetrate into the 
mucin network (diffusion theory) strengthening the adhesive bond.  
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Fig. 1.2: Contact and consolidation stage of the mucoadhesion process [10,49] 
 
1.2.4 Mucoadhesive drug delivery systems 
The extensive research in the field of mucoadhesion led to the development of drug delivery 
systems directed to practically all possible mucosal tissues, such as the nasal [14], buccal [56], 
ocular [57], vaginal [58], gastric [59], small intestinal [60], and colonic mucosa [61]. 
Mucoadhesive drug delivery systems are solid or semi-solid dosage forms, i.e. tablets, 
multiparticulates, patches, films, or gels, depending on the site of administration. For example 
in buccal delivery, mucoadhesive films were described as highly suitable dosage forms due to 
the flexibility and comfort [56]. But also gels were produced for buccal delivery, such as 
ORABASE®, a mucoadhesive paste which protects sore areas in the mouth. Tablets are by far 
the most developed and investigated mucoadhesive dosage forms, but current market products 
(e.g. Aftach) are still limited [62]. 
For gastrointestinal delivery, multiparticulates are favorable compared to single-unit dosage 
forms due to better distribution along the intestinal wall, and the increased total surface area 
available for adhesive bonds. Furthermore, the gastrointestinal transit of multiparticulate 
formulations is less variable than single-units, and transit through the large intestine is slower 
due to a sieving effect, with monolithic dosage forms moving faster [63,64]. Therefore, 
considerable amount of work has been carried out on the development of mucoadhesive 
nanoparticles [65–67], microparticles [68–71], and pellets in the millimeter range [61,72]. 
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1.2.5 In vitro methods to study mucoadhesion 
In vitro test methods were extensively applied to identify new candidates of mucoadhesive 
polymers, and to evaluate the mucoadhesive potential of newly developed formulations. The 
many available techniques can be categorized into direct and indirect methods [73]. Direct 
methods either measure the force to break a mucoadhesive bond (e. g. tensile detachment [74], 
atomic force microscopy [75]), or the time a mucoadhesive dosage form can remain on a 
mucosal surface when exposed to drag forces of a flow (e.g. flow detachment [76], rotating 
cylinder method [77]). For these experiments, usually animal mucosal tissues are used. 
Alternatively, artificial substrates can also be applied with the aim of improving the 
reproducibility of the results [78]. Indirect methods investigate parameters which are related to 
mucoadhesive properties. For example, the molecular interactions between polymer and 
mucins can be measured by rheological measurements [79].  
In tensile detachment methods, modified balances or tensile testers are typically used to 
measure the adhesive bond between the polymers and the mucosal tissue. Many research 
groups adopted and modified the method which was first described by Ch’ng et al. in 1985 
[74]. The easy sample preparation, the short run time of the experiment, and the high detection 
sensitivity are advantages which made the tensile test the most applied method in the research 
of mucoadhesive polymers. The instrument setup should control either the force to be applied 
or the speed of detachment in order to record a detachment profile. The profile gives 
information about the change in the force applied as a function of the distance between the 
polymer sample and the substrate. Earlier studies only reported the maximal force required to 
detach the mucoadhesive dosage form from the mucosal tissue [74,80–82]. Later, the total 
work of adhesion was introduced to describe the whole process of detachment, which is 
simply the area under the curve in the detachment profile [83]. It was suggested that not only 
the adhesiveness between polymers and mucins, but also their deformation and mechanical 
properties make a contribution to the complex detachment process [12].  
The principle of the flow-detachment method is to measure mucoadhesion based on the 
resistance to a flow and was first described by Rao and Buri [84][77] as shown in Fig. 1.3. 
This method was later adapted by other researchers and alternative techniques were reported, 
namely the falling liquid film method [68], continuous-flow adhesion cell [85], retention 
model apparatus [76], and particle-retention assay [86]. Since mucoadhesive formulations aim 
to prolong mucosal residence time, the results of such experiments are mostly given in 
retained percentage of the initially applied formulation, after a defined period of time. Flow 
detachment assays were preferably applied to investigate bioadhesion of microparticles 
[68,84,87–91] and polymer solutions [85,92–94] for drug delivery to the gastrointestinal 
mucosa. These methods also found application for the evaluation of nasal [95], esophageal 
MUCOADHESION          1.2 
 
 
11 
[76] and ocular delivery systems [96]. The disadvantage of a flow-detachment method is the 
need of a flow device which has to be developed in house. As a consequence, different designs 
and method parameters were used, which makes it difficult to compare the results between 
different research groups. Mikos and Peppas [97] were the only ones who used a closed 
channel. The open channel was used in numerous variations. For example, the flow channel of 
Rao and Buri [84] was semi-cylindrical and had one nozzle for inlet flow, whereas Bachelor et 
al. [76] have used a flat channel with three nozzles for inlet flow for better distribution of the 
medium (see Fig. 1.3).  
 
  
 
 
Fig. 1.3: Schematic presentation of two different flow-channel designs reproduced from Rao 
and Buri (left [84]), and Batchelor et al. (right [76]).  
 
In the rotating cylinder method, mucoadhesive microparticles or tablets are also subject to 
drag forces. However, the difference is that the mucosa covered with adhering particles is 
moved relative to the medium. The mucosal tissue is mounted around a basket commonly used 
in USP I dissolution studies, and the mucoadhesive formulation is applied on the substrate. In 
case of tablets or test discs, the time of adhesion is measured [77], whereas for microparticles 
the percentage of remaining particles is determined after a specified time [98].  
With the rheological approach it is possible to investigate the interactions of polymeric gels 
with the mucin glycoprotein, since interpenetration of the two polymers can be detected by the 
change of the rheological properties [99]. In general, the mixture of a hydrated mucoadhesive 
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polymer and mucin shows increased viscosity when determined experimentally in comparison 
to the theoretical cumulative viscosity calculated from the individual components. This 
increased viscosity is due to the molecular interactions, which can be based on chain 
interlocking, conformational changes, and chemical interaction. Therefore, the relative change 
in viscosity of the solution, also described as rheological synergism of mucus and polymer, 
can be used as an indirect quantification of mucoadhesion [79,100].  
1.2.6 In vivo methods to study mucoadhesion 
In vivo methods were applied to evaluate the usefulness of mucoadhesive formulations under 
physiological conditions. In vitro tests are often performed under standardized conditions, and 
do not resemble the complex environment of the gastrointestinal lumen and mucosa 
Especially, in case of mucoadhesive formulations intended for gastrointestinal delivery, 
factors like volume of fluid available, bowel movement, enzymatic activity, and the presence 
of food contents are in general difficult to simulate.  
In vivo studies with mucoadhesive microparticles can be performed in animals, preferably 
fasted rats, by oral administration of a known number of microparticles and subsequent 
dissection of the different intestinal segments [101]. The percentage of the recovered 
microparticles at different time points and segments can be used to estimate the 
gastrointestinal transit time of mucoadhesive formulations in comparison to non-
mucoadhesive control. To improve the reliability of the quantification method, mucoadhesive 
microparticles were fluorescently labelled, and the number of particles in the different 
segments quantified using a fluorescence microscope. Chickering et al. [102] have used 
radiopaque barium to label mucoadhesive microspheres. After oral administration, the feces of 
the rats were collected by a custom-built sampling robot at pre-defined time intervals. The 
gastrointestinal lumen and the collected samples were X-rayed and analyzed for particle 
content.  
The gamma-scintigraphy technique is a powerful tool to visually track in vivo the fate of orally 
administered dosage forms throughout the gastrointestinal tract [103,104]. Such clinical trials 
in humans were also performed for investigation of gastrointestinal transit time of 
mucoadhesive formulations [105–107]. The principle in gamma-scintigraphy studies is to 
incorporate a suitable gamma-emitting radioisotope, such as technetium-99m, indium-111, or 
samarium-153. The radioisotopes can be generated from stable nuclides, such as samarium-
152, using neutron activation, which is done in a nuclear reactor by bombardment with 
neutrons. This means that the preparation of the pharmaceutical dosage form can be conducted 
with a non-activated marker. However, the high energies during neutron activation can lead to 
crosslinking or degradation of polymers and drug degradation. For these reasons, only a short 
activation process is used, and the effect of neutron activation on drug release, drug content 
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and impurities should be investigated in vitro prior to administration in vivo. After activation, 
the dosage form is stored until alpha radiation is harmless, and gamma radiation has decreased 
to approximately 1 MBq [108]. Gamma rays can be transferred into images using a gamma 
camera. Samarium-153 is of major clinical relevance, since the relatively short half-life of 
46.3 h is well suited for carrying out a visualization study of gastrointestinal transit of dosage 
forms over few days [109].  
Bioavailability studies were also performed for indirect determination of mucoadhesion by 
comparison to a non-mucoadhesive control formulation [107,110]. Ideally, sustained-release 
formulations are tested containing a drug which is absorbed only in a short part of the 
gastrointestinal tract in order that non-mucoadhesive formulations do not reach bioavailability 
values close to 100%. A significantly increased bioavailability of the mucoadhesive 
formulation can then be indirectly explained by the prolonged gastrointestinal transit time.  
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1.3 Colon drug delivery 
The large intestine was recognized as a potential site of drug delivery for the local treatment of 
colonic diseases, as the treatment of chronic inflammatory diseases with potent substances is 
often accompanied by severe systemic side effects. The main rationale for local drug delivery 
is to have increased drug concentrations directly at the site of action, with the benefits of 
decreasing drug doses, plasma concentrations, and adverse drug effects. Colonic drug delivery 
can also be an efficient strategy to circumvent metabolic degradation by enzymes or active 
efflux by transporters in the small intestine [111]. Due to the reduced proteolytic activity, the 
colon has been also often pinpointed as a potential site for delivery and absorption of peptides 
[10,112]. Time-delayed drug delivery systems were one of the first formulation approaches for 
colonic delivery. However, due to the wide intra- and intersubject variability of 
gastrointestinal transit time, these formulations lacked precision of releasing the drug in the 
colon. Only when the complex environment and physiology of the large intestine was 
understood in more details, colon-specific characteristics could be identified as a trigger for 
drug release. As a result, more efficient formulation strategies were developed, for instance 
coating technologies which are pH-responsive or degradable by the colonic microflora. In this 
Chapter 1.3, the relevant background knowledge related to colon drug delivery is summarized, 
and in particular, the current status of the development of multiparticulate colon drug delivery 
systems was reviewed. 
1.3.1 Anatomy and physiology of the large intestine 
The large intestine extends from the ileocecal junction to the anus, including distinct segments 
in following order: cecum, ascending colon, transverse colon, descending colon, sigmoid 
colon, and rectum (see Fig. 1.4). The main functions of the large intestine are the resorption of 
water and electrolytes, and retention of the solid stool until a convenient time of defecation. In 
healthy humans, the chyme coming from the ileum to the colon has a mean flow rate of 
1-2 liter per day. The absorptive capacity of the colon can be up to 4 liter per day, and the 
residual water content in the stool is less than 10% [19]. According to the results of an MRI 
study conducted by Schiller et al. [113], the fluid volume in the large intestine was highly 
variable among the subjects, and also depending on food intake. In fasted state, the total 
colonic fluid volume ranged from 1-44 ml (median = 8 ml), and in the fed state from 2-97 ml 
(median = 18 ml).  
The highly viscous feces are transported towards the rectum by very intense and prolonged 
contractions, the so-called mass movements or giant migrating contractions. But also 
segmental contractions to mix the intestinal content, and antiperistaltic contractions towards 
the ileum to retard the movement of fecal mass are observed [114]. The large intestine has a 
length of approximately 1.6 m when measured post mortem, which is much smaller than the 
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small intestine (6.0-6.7 m) [115]. There are additional factors why the large intestine is 
considered to be less effective for drug absorption compared to the small intestine, such as the 
absence of microvilli and organic nutrient transporters, the increased thickness of the mucus 
layer, and the higher viscosity of the intestinal content. The latter leads to a lower drug 
diffusion coefficient, and affects negatively the mixing of the colonic content, reducing the 
drug concentrations close to the epithelium[19].  
 
Fig. 1.4: Anatomy of the large intestine (adapted from [19]). 
The gastrointestinal transit time is an important factor in the design of targeted drug delivery 
systems, because it can affect disintegration time of the dosage form, or the location and 
extent of drug dissolution and absorption. However, the intra- and intersubject variability of 
transit time, especially through the colon, is very high [2].The mean transit time of a dosage 
form through the small intestine is fairly constant, ranging from 3-4 h, in both fed and fasted 
state, and regardless of the size of the dosage form [116]. Furthermore, it was reported that the 
physical state of the dosage form, i.e. liquid or solid, does not affect the transit speed through 
the small intestine [117]. After passage through the small intestine, the dosage form rests in 
the cecum before it enters the colon for a variable period of time (0-12 h) [7], and multiple-
unit formulations were observed to regroup [118]. According to a scintigraphy study of 
Abrahamsson et al. [63], the colonic transit time is different for pellets and tablets, which 
ranged within 6 to 48 h, and 3.8 to 26 h, respectively. Despite the large variations for both 
dosage forms and the wide overlapping time range, tablets showed a clear trend of shorter 
transit time. 
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The pH in the gastrointestinal tract gradually increases from the stomach to the distal small 
intestine due to the bicarbonate secretion in the small intestine. The bicarbonate secretion rate 
is regulated by the hormone secretin and is the highest in the duodenum providing efficient 
neutralization of the gastric pH [119]. In contrast to the common belief that pH continues 
rising also along the large intestine up to pH 7-8 [120], various studies have demonstrated the 
opposite, that pH is highest in the terminal ileum (pH 7.5) and drops significantly in the cecum 
to pH 6.4-6.0, followed by a gradual increase from the right to the left colon.[121,122]This pH 
drop in the caecum is mainly due to bacterial fermentation of polysaccharides generating short 
chain fatty acids (such as acetic, propionic, and butyric acid) which contribute to reduce the 
pH [123,124]. 
The human colon is hosting up to 400 different species and subspecies of bacteria [19], and 
more than 99% of the colonic microflora are obligate anaerobes [24,125]. Most anaerobic 
species belong to the Bacteroides, Bifidobacteria, and Eubacteria. Other Gram-positive 
bacteria present in the colon are the Enterococci, Clostridia, and Enterobacteria [126]. The 
high diversity and colonization of bacteria in the colon compared to the microflora in the 
stomach and the proximal small intestine stems from the favorable changes of environmental 
conditions, such as the decreased acidity and motility as well as the presence of a vast amount 
of nutrients which escape digestion and absorption in the upper small intestine. The chyme, 
containing polysaccharides indigestible for humans, is fermented by hydrolytic enzymes (β-
glucuronidase, β-xylosidase, α-L-arabinosidase, and β-galactosidase), and reductive enzymes 
(nitroreductase, azoreductase, deaminase, and urea dehydroxylase) [111,127]. In addition to 
the metabolic activity, we profit a great deal from the high diversity of the gut flora due to 
secretion of a number of signaling factors supporting our immune system, and due to 
protection of the intestinal mucosa from overpopulation by pathogenic microbes [128]. It is 
therefore not surprising that a misbalance of the gut flora can be a crucial factor in the 
pathogenesis of colonic diseases such as IBD or irritable bowel syndrome (IBS) [125].  
1.3.2 Diseases of the large intestine 
Ulcerative colitis and Crohn’s disease are chronic inflammatory conditions of the gastro-
intestinal mucosa. They are both referred to IBD due to a number of common features. IBD 
are more prevalent in developed countries, and the incidence of ulcerative colitis is relatively 
high with 1.2 to 20.3 cases per 100,000 persons per year [129]. In ulcerative colitis, 
manifestation of the disease is limited to the rectum and the large intestine, whereas in Crohn’s 
disease the whole gastrointestinal tract from the oral cavity to the rectum can be affected. The 
main characteristic symptom of IBDs is diarrhea mixed with blood and mucus. The disease 
can be classified by the severity of the symptoms [130] or by the extent of involved intestinal 
segments [131]. In contrast to Crohn’s disease, ulcerative colitis can have a mild disease 
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progression, and complete cure is only possible by surgery. In mild to moderate cases of 
ulcerative colitis, the anti-inflammatory drug mesalazine (e.g. Asacol®) is used as first-line 
therapy for induction and maintenance of remission [132]. Since autoimmune phenomena are 
involved in the pathogenesis of IBDs, they are also managed with immunosuppressive drugs 
such as corticosteroids (prednisone and budesonide), monoclonal antibodies (i.e. infliximab), 
and others (azathioprine), depending on the severity of the disease and the response of the 
patient [133]. These medicines can produce strong systemic side effects, including mortality. 
The most prominent side effects in the treatment with corticosteroids are, besides many others, 
water retention in the face and acne [134]. The treatment with immunosuppressives is often 
accompanied by serious infections [135]. Hence, novel formulation strategies targeting the 
diseased tissue are of high clinical relevance either for existing molecules or new chemical 
entities (NCEs) [136]. 
Pseudomembranous colitis (PMC) is an inflammation of the large intestine most often caused 
by overgrowth of Clostridium difficile (C. difficile) bacteria. The major cause for PMC is the 
elimination of the normal microflora during antibiotic therapy allowing pathogenic bacteria to 
flourish. Therefore, PMC is also referred to C. difficile colitis or antibiotic associated colitis. 
In most cases, the inflammation is caused by the virulence factors toxin A and toxin B. They 
are internalized by the enterocytes via receptor binding, where they disrupt the cell 
cytoskeleton and activate an inflammatory immune response [137].  
Colon cancer is the third most common type of cancer, and involves around 10% of all cancer 
cases [138]. In early stage of non-metastatic colon cancer, surgical dissection is the most 
effective treatment. However, a high risk of recurrence remains, and adjuvant chemotherapy 
was demonstrated to be inevitable for successful therapy of colon cancer. Besides the standard 
combination therapy of 5-fluorouracil and leucovorin, additional treatment with other 
chemotherapeutic compounds such as oxaliplatin, capecitabine, and irinotecan can increase the 
survival rate depending on the stage of the cancer [139].  
1.3.3 Technologies for colon drug delivery  
Colon drug delivery systems for oral administration have the advantage to reach the entire 
large intestine, i.e. from the ileo-colonic region to the rectum, whereas rectally administered 
formulations, such as suppositories or foams, only reach the lower part of the rectum. Drug 
delivery to the colon via the oral route can be achieved by advanced formulation technologies 
triggering the drug release only upon arrival in the ileo-colonic region. Alternatively, the drug 
itself can be chemically modified to a prodrug which undergoes biotransformation to the 
active parent drug under colon-specific conditions.  
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The prodrug approach was successfully applied to the anti-inflammatory drug mesalazine 
(5-aminosalycilic acid, 5-ASA) used in the treatment of ulcerative colitis and Crohn’s disease. 
Sulfasalazine, olsalazine, and balsalazide are well-known examples for colon-specific 
prodrugs having a second moiety coupled to 5-ASA via an azo bond (R1-N=N-R2) [140]. An 
important characteristic of colon-specific prodrugs is a low and reproducible absorption rate in 
the small intestine. When administered orally, about 20% of sulfasalazine is systemically 
absorbed [141]. In the colon, the remaining fraction of sulfasalazine is transformed to 5-ASA 
and sulfapyridine moieties by bacterial azoreductase which cleaves the azo bond. The 
absorption of 5-ASA in the colon is relatively low as the bioavailability ranges from 11-33% 
[140]. Sulfapyridine has been found to be responsible for adverse drug effects. Therefore, 
5-ASA prodrugs based on azo-linked polymers have also been developed to decrease systemic 
absorption and reduce side effects [142]. The azo-coupling to mucoadhesive polymers 
presents an interesting strategy for more effective local therapy [143,144], but the high amount 
of polymers needed to reach the required dose of 5-ASA is a drawback of using polymeric 
prodrugs. Colon-specific prodrugs were also developed for glucosteroids such as 
dexamethasone, prednisolone, hydrocortisone, and fludrocortisone by coupling the highly 
polar moieties galactose or glucose via a β-glycosidic bond [145,146]. 
Time-delayed release systems for drug delivery to the colon follow the principle of having a 
predetermined lag time for drug release, which matches the transit time through the small 
intestine. The PulsincapTM technology was one of the first delivery devices based on the lag-
time principle [147]. It consists of a capsule with an insoluble body and a soluble cap. The 
body of the capsule is filled with the drug and closed with a hydrogel plug. After a 
predetermined time of swelling, the plug is pushed out and the drug starts to release [148]. The 
problem of variable gastric emptying can be avoided by coating the whole drug delivery 
system with enteric polymers. In an attempt to improve the PulsincapTM system, an erodible 
tablet instead of the swelling hydrogel was used [149]. Despite the relatively consistent transit 
time through the small intestine [116], various studies demonstrated a poor precision of time-
delayed delivery systems to release the drug at the intended site [146,147], which might be 
due to variability in pH and consequent localization of enteric coating dissolution exposing the 
drug core .  
The use of pH-dependent film coatings is the most popular strategy for targeted drug delivery 
to the colon [120,152,153]. The polymers for pH-triggered drug release are usually 
methacrylic acid - methyl methacrylate copolymers (Eudragit®, Evonik AG) or 
hydroxypropyl methylcellulose (HPMC) derivatives such as HP-50 and HP-55, which have a 
specific and narrow pH range where they start to dissolve. For example, Eudragit® S dissolves 
at pH ≥7, which is considered as an optimized enteric coating formulation for colon delivery. 
COLON DRUG DELIVERY          1.3 
 
 
19 
More pH-dependent coating polymers can be found in the review of Madhu et al. [154]. 
Ashford et al. [155] investigated the usefulness of pH-dependent model formulations coated 
with Eudragit® S by determining the site of disintegration in vivo using gamma-scintigraphy. 
In some cases, disintegration occurred already in the ileum, whereas in another case the tablet 
travelled until the splenic flexure before the drug was released. This lack of site specificity can 
be due to the high intra -and intersubject variability of pH and exposure time to the 
gastrointestinal fluid and also due to the inconsistent acidity gradient along the gastrointestinal 
tract with the highest pH in the ileum (pH 7.5), followed by the sharp drop of pH in the cecum 
(6.0).  
Biodegradable polymeric film coatings follow the same principle as the prodrugs. They are 
degraded by the enzymatic activity of colonic bacteria with the advantage of allowing higher 
drug doses which are released at once. Azopolymers were used for delivery of peptides 
(insulin and vasopressin) [156,157], and various small molecules [158,159]. Naturally 
occurring polysaccharides and its derivatives, such as amylose [160], pectin [161], chitosan 
[162], inulin [163], and dextran [164] are biodegradable polymers which were also exploited 
in terms of colon-specific targeting. To test the usefulness of such coatings, drug release in 
appropriate media simulating the enzymatic activity of the colonic microflora can be measured 
according to Molly et al. [165]. However, according to several in vivo studies, the 
reproducibility of such microbially triggered release systems can also be affected by intra- and 
intersubject variability of the intestinal microflora [150,157,166].  
Novel approaches are focusing on the combination of two mechanisms, preferably enzymatic 
and pH-sensitive systems, since gamma-scintigraphy studies have shown high reproducibility 
regarding the site of disintegration [167,168]. Such coating systems are less affected by intra- 
and intersubject variability, because in case that one mechanism fails, there is still a “back-up” 
mechanism acting as a trigger of complete drug release. 
1.3.4 Multiparticulate colon drug delivery systems 
There is a clear trend in colon drug delivery to develop multiparticulate formulations rather 
than single-unit systems. The advantages are similar as for mucoadhesive multiparticulates 
described in Chapter 1.2.4, i.e. prolonged transit time, closer contact to the diseased tissue, and 
more reproducible drug release [169,170]. The development of colon-targeted pellet 
formulations has already led to the launch of several products in the market (Apriso and 
Salofalk Granu-Stix) [169], whereas colonic-targeted formulations based on microparticles or 
nanoparticles require further development, especially regarding its toxicity profile and 
manufacturability at industrial scale.  
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Most pellet formulations for colon delivery have been prepared by extrusion-spheronization. 
The drug can be extruded together with a colon-specific polymer such as Eudragit S [171], 
chitosan [172], or pectin [173]. Another popular method is to prepare drug-loaded pellets 
which are subsequently film-coated with a pH-dependent or enzymatically-degradable 
polymer, as described for 5-ASA [160,174–177], budesonide [178], and ibuprofen [171]. 
Alternatively, drug layering onto nonpareil starter pellets and subsequent film coating with 
colon-targeting polymers can be carried out using the fluidized-bed process [179,180]. 
Ionotropic gelation of pectin with zinc or calcium ions was also reported for fabrication of 
colon-specific pellets, where the drug is incorporated during the crosslinking process [181–
183]. Various modifications of such pectin-based pellets have been investigated for colon drug 
delivery [184–186]. Numerous in vivo studies have been carried out showing the potential of 
colonic-targeted pellets to improve the therapeutic outcome in rats [156,162,176,178,187–
193], mice [194], rabbits [195], dogs [196], and humans [197,198]. 
Nanoparticles for colon drug delivery were first developed and described by Cheng and Lim 
[199]. Their preparation method of insulin-loaded nanoparticles was based on ionotropic 
gelation of the bacterial-degradable polymer pectin. The rationale of using nano-sized carriers 
for colon delivery is a lower transit time and a faster degradation of the coating or matrix upon 
arrival in the ileo-colonic region [200]. Furthermore, Lamprecht et al. have demonstrated a 
size-dependent accumulation of polystyrene particles in inflamed mucus tissue of colitis-
induced rats. Highest binding affinity was observed for nanoparticles (100 nm), whereas 
relative deposition of microparticles (1 µm and 10 µm) was significantly decreased. As a 
consequence of these breakthrough results, the development of colon-specific nanoparticles 
gained a lot of interest, and several in vivo studies were carried out as summarized in Table 
1.1. Most formulation approaches were based on anti-inflammatory drugs, and incorporation 
of pH-sensitive polymers (Eudragit® S100) into the particle shell. To test the usefulness of 
such nanoparticulate drug delivery systems in vivo, many researchers used the colitis-induced 
rat or mouse model to investigate the effect on the extent of inflammation after oral 
administration. A more recent advancement by Vong et al. [201]is the use of redox polymers 
which specifically accumulate in inflamed tissues (mechanism unclear) and eliminate the 
reactive oxygen species (ROS), eventually reducing the extent of inflammation. 
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Table 1.1: In vivo evaluation of nanoparticles for colon drug delivery. 
Colon-specific polymer  Preparation method Drug type (drug) In vivo method  Ref. 
Pectin Ionotropic gelation  Peptide (insulin) (in vitro release studies) [199] 
Chitosan and chitosan 
derivatives 
Polyelectrolyte 
complexation 
Peptide (insulin) Hypoglycemic effect in 
rats 
[202] 
Chitosan and alginate Double emulsion/ 
solvent evaporation 
Anti-inflammatory 
tripeptide  
Reduction of 
inflammation in colitis-
induced mice 
[203] 
Eudragit® S100 
 
Emulsification-
diffusion 
Anti-inflammatory 
(budesonide) 
Reduction of 
inflammation in colitis-
induced rats 
[204] 
Eudragit® S100 Emulsification-
diffusion 
Anti-inflammatory 
(curcumin) 
Reduction of 
inflammation and 
distribution in colitis-
induced mice  
[205] 
Eudragit® S100 oil-in-water emulsion/ 
solvent evaporation 
Anti-inflammatory 
(budesonide) 
Reduction of 
inflammation in colitis-
induced mice 
[206] 
Eudragit® RS PO  Emulsification-
diffusion 
Fluorescent-
marker  
Distribution in mice gut [207] 
Eudragit® S100 and azo-
polyurethane 
oil-in-water emulsion/ 
solvent evaporation 
Fluorescent-
marker 
Distribution in colitis-
induced rats 
[208] 
Redox block copolymer Self-assembly Reduction of ROS Cellular uptake in colitis-
induced mice 
[201] 
 
Microparticles for colon delivery are an interesting alternative to nanoparticles as they are not 
internalized by epithelial cells, and hence, there is a much lower risk of systemic drug toxicity. 
Lorenzo-Lamosa et al. [209] have prepared drug-loaded chitosan microspheres by spray-
drying which were subsequently encapsulated in Eudragit® L100 and Eudragit® S100 using 
an oil-in-oil solvent evaporation method. In vitro drug release was continuous for several 
hours when measured at pH 7, whereas no drug dissolution was observed in an acidic buffer. 
There have been numerous reports on multiparticulate colon drug delivery systems in the 
micro-size range, most of them based on bacteria-degradable or pH-sensitive release 
mechanisms. However, only a few have been tested in vivo, as summarized in Table 1.2.  
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Table 1.2: In vivo evaluation of microparticles for colon drug delivery. 
Colon-specific polymer  Preparation method Drug type In vivo method Ref. 
Chitosan and alginate Spray drying Anti-inflammatory 
(budesonide) 
Reduction of inflammation 
in colitis-induced rats 
[217] 
Chitosan and 
polyethylene glycol 
Emulsion crosslinking 
solvent evaporation 
Anticancer           
(5-fluorouracil) 
Distribution in mice gut 
(X-ray) 
[211] 
Chitosan Spray drying Antibiotic 
(levofloxacin) 
Pharmacokinetics and 
distribution in rat gut 
[214] 
N-Succinyl-chitosan Spray drying and 
freeze drying 
Anti-inflammatory 
(5-ASA) 
Reduction of inflammation 
in colitis-induced rats 
[216] 
Chitosan and Eudragit® 
S100 
Emulsion/ solvent 
evaporation 
Anti-inflammatory 
(5-ASA) 
Reduction of inflammation 
in colitis-induced rats 
[218] 
Eudragit® S100 Double emulsion/ 
solvent evaporation  
Peptide (insulin) Hypoglycemic effect in 
rabbits 
[219] 
Eudragit® S100 Oil-in-oil emulsion/ 
solvent evaporation 
Fluorescent 
marker 
Pharmacokinetics in colitis-
induced rats 
[220] 
Eudragit® S100 Spray freeze-drying Fluorescent 
marker 
Pharmacokinetics and 
distribution in rat gut  
[210] 
Eudragit® P-4135F Double emulsion/ 
solvent evaporation 
Anti-inflammatory 
(calcitonin) 
Pharmacokinetics in rats [221] 
Eudragit® S, L, L55 Oil-in-oil emulsion/ 
solvent evaporation 
Anti-inflammatory 
(prednisolone) 
Pharmacokinetics in rats [222] 
Eudragit® S100 and 
dextran 
Emulsion crosslinking Anticancer         
(5-fluorouracil) 
Pharmacokinetics and 
distribution in rat gut 
[213] 
Assam Bora rice starch Double emulsion/ 
solvent evaporation 
Antibiotic 
(metronidazole) 
Distribution in rat gut  [215] 
Guar gum Emulsion crosslinking Anti-inflammatory 
(budesonide) 
Pharmacokinetics and 
distribution in rat gut 
[212] 
 
Pharmacokinetic investigations have often been used for determining the delay of drug release 
in comparison to control particles. However, for estimation of the colon-delivery potential, 
pharmacokinetic data have to be compared with gastrointestinal transit time. This was done by 
measuring the particle distribution in the gut at various time points using different techniques, 
e.g. fluorescence labeling [205,208,210,211], X-ray analysis [207], or drug quantification by 
HPLC [212–215]. Most of these multiparticulate colon drug delivery systems based on 
nanoparticles or microparticles have shown a potential benefit in the animal models. However, 
so far no clinical trials have been performed in humans to support this view.  
Mucoadhesive functionalization of multiparticulate colon drug delivery systems can increase 
the colonic transit time, and hence, they can improve the therapeutic efficiency. Varum et al. 
[61] have developed mucoadhesive pellets coated with an Eudragit® S double layer system 
(inner layer pH 8, outer layer unbuffered) to accelerate complete disintegration of the coating 
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oncethe pH trigger is reached. Bautzova et al. [191] have developed chitosan pellets by 
extrusion-spheronization, which were subsequently coated with Eudragit® FS 30D. These 
mucoadhesive pellets showed a significantly better pharmacological effect in the colitis-
induced animal model compared to non-mucoadhesive pellets. Mucoadhesive microparticles 
for colon delivery have also been developed and investigated in vivo [215,216]. This literature 
research about multiparticulate colon drug delivery system has shown that most preparation 
methods to obtain nano- or microparticles were based on emulsification or ionic-gelation 
techniques. However, mucoadhesive formulations based on porous nano- or microcarriers 
were not reported yet.  
1.3.5 Porous microcarriers for the development of mucoadhesive microparticles 
In general, processing of microcarriers is easier compared to nanocarriers due to the improved 
flowability of larger particles and the possibility of using standardized processes suitable for 
scale-up. Pellets in the millimeter range would have even better flowability, but microcarriers 
are expected to show better mucoadhesive performance due to the increased surface area 
available for mucoadhesive bonds compared to large tablets or pellets [47,55,69,223]. The 
increased colonic transit time for smaller particles also favors the use of microcarriers. 
The extrusion/spheronization method was often used for preparation of mucoadhesive 
multiparticulates probably due to the simple preparation method. However, this method is only 
suited for pellets in the millimeter range. For preparation of mucoadhesive microparticles, 
drug-loading or drug-layering of microcarriers has the advantage that an established and easy 
scalable process can be used (such as the fluidized bed process) compared to the 
emulsification or ionic-gelation methods which are difficult to transfer to industrial scale. 
Drug loading of porous microparticles might be advantageous in comparison to drug layering 
of non-porous microparticles since the drug is deposited in the carrier skeleton better 
stabilizing the mucoadhesive coating during drug dissolution and drug diffusion through the 
swollen mucoadhesive outer coating. 
There are a few candidates of commercially available porous microparticles which could be 
used as drug carrier for the intended mucoadhesive multiparticulate formulation. However, the 
particle size is a critical parameter and not all microparticles meet the desired requirements. 
On the one hand, the microparticles should be as small as possible to have optimal 
mucoadhesion properties related to the large specific surface area, but on the other hand, the 
increasing cohesive forces of smaller particles can cause manufacturing issues related to poor 
powder flowability. The flow properties might be critical for pharmaceutical excipients with 
median particle diameters <30 µm, as for example observed for microcrystalline cellulose 
(MCC, Avicel PH 105) and hydroxypropyl cellulose (HPC) with median particle sizes of 20 
and 29 µm, respectively [224]. 
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The granulated fumed silica AEROPERL® 300 was considered as a potential candidate due to 
the high porosity, the small particle size (30 µm), and its good flowability properties. 
However, the small pore size of 30-40 nm [225,226] might be disadvantageous when high 
drug loads are desired. Neusilin US2 is granulated magnesium aluminometasilicate with small 
particle size (mean 60-120 µm) and high porosity, but the mean pore size of 5 nm is even 
smaller than for AEROPERL®.  
FCC (Omyapharm) is a novel pharmaceutical excipient with unique properties, such as small 
particle size (5-15 µm), high porosity (>70%, v/v), and biodegradability [227–231], and due to 
its large pore size diameter in the outer stratum (~1 µm), which is promising for high drug 
loads, it has a relevant advantage compared to alternative microcarriers mentioned before.  
Instead of coating individual particles with colon-targeting polymers, the mucoadhesive 
microparticles were filled into capsules which could be coated with a colonic-targeted coating 
layer. The feasibility of coating hard-shell HPMC capsules in a pan coater with a colon-
specific polymer was already demonstrated [232], and hard gelatin capsules are also feasible 
for application of enteric coatings [233]. However, hydration and swelling of mucoadhesive 
polymers inside capsule vehicles has been observed in an in vivo study in beagle dogs by 
McGirr et al. [234] resulting in an incomplete release of the polymer from the capsules. 
Therefore, dispersibility enhancement was an additional research focus to avoid agglomeration 
of mucoadhesive microparticles prior to release from the capsule.  
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2 Aims 
Drug delivery of mucoadhesive microparticles to the colon has great potential for local 
treatment of colonic diseases due to prolonged transit time and improved therapeutic efficacy. 
However, the large intestine presents a challenging environment, and so far, no in vivo data on 
the usefulness of oral mucoadhesive formulations in the human colon are available, despite 
extensive preclinical data. The aim of this project was to develop a mucoadhesive and 
multiparticulate formulation platform for colonic delivery. The formulation concept illustrated 
in Fig. 2.1 consists of a colonic-targeted capsule filled with the mucoadhesive microparticles. 
The focus of the work presented here was on the development of the mucoadhesive 
microparticles, i.e. on the drug loading of porous microcarriers and subsequent coating with a 
mucoadhesive polymer. The development of the enteric coating of the capsule for colonic 
targeting is not part of this thesis, as it was carried out by our collaboration partner Tillotts 
Pharma, based on their patented technology and internal know-how. To achieve a formulation 
prototype feasible for a Phase 1 study, following three aims were defined and pursued.  
I) Evaluation of a suitable porous microcarrier with small mean particle size (10-100 µm) and 
high loading capacity. The drug loading method should be applicable to metronidazole and 
ideally to various other drug substances.  
II) Development of a coating method to functionalize the drug-loaded microparticles with a 
mucoadhesive polymer. For optimization of the mucoadhesive microparticles, the 
development of a particle retention assay was envisaged, including the design of a flow-
channel device and the development of a sensitive and reliable particle-quantification method. 
III) Method optimization towards a scalable and industrially applicable method for preparation 
of mucoadhesive microparticles to manufacture of clinical batches for a Phase-1 study.  
 
Fig. 2.1: Proposed formulation concept of the mucoadhesive and multiparticulate colon drug 
delivery system.  
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3 Peer-reviewed publications 
3.1 Drug loading into porous microcarriers 
 
Drug loading into porous calcium carbonate by solvent evaporation 
Daniel Preisig1, David Haid1, Felipe J. O. Varum2, Roberto Bravo2, Rainer Alles1, Jörg 
Huwyler1, Maxim Puchkov1 
1 Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 
Basel, Switzerland 
2 Tillotts Pharma AG, Baslerstrasse 15, 4310 Rheinfelden, Switzerland 
 
 
 
Fig. 3.1: Graphical abstract of the publication. 
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3.2 Mucoadhesive coating and in vitro evaluation 
 
Marker-ion analysis for quantification of mucoadhesivity of microparticles in 
particle-retention assays 
Daniel Preisig1, Michael Weingartner1, Felipe J. O. Varum2, Roberto Bravo2, Rainer Alles1, 
Jörg Huwyler1, Maxim Puchkov1 
1 Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 
Basel, Switzerland 
2 Tillotts Pharma AG, Baslerstasse 15, 4310 Rheinfelden, Switzerland 
 
 
Fig. 3.2: Graphical abstract of the publication. 
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3.3 Preparation of optimized mucoadhesive microparticles  
 
Mucoadhesive microparticles for local treatment of gastrointestinal diseases 
Daniel Preisig1, Roger Roth1, Sandy Tognola1, Felipe J. O. Varum2, Roberto Bravo2, Yalcin 
Cetinkaya2, Jörg Huwyler1, Maxim Puchkov1 
1 Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 
Basel, Switzerland 
2 Tillotts Pharma AG, Baslerstrasse 15, 4310 Rheinfelden, Switzerland  
 
 
Fig. 3.3: Graphical abstract of the publication. 
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4 Clinical study protocol 
To investigate the gastrointestinal transit times of two different multiparticulate formulations 
(mucoadhesive vs. non-mucoadhesive), a pharmaco scintigraphy study on human subjects 
was designed in the scope of this collaboration project. The preparation of the Phase-1 
clinical trial was managed and performed by Tillotts Pharma and the University Hospital. In 
the context of the global project, the study protocol is here briefly described  
Formulation A consists of mucoadhesive microparticles and is expected to show increased 
colonic transit time in comparison to Formulation B which consists of non-mucoadhesive 
microparticles. Both formulations contain the antibiotic drug metronidazole benzoate 
(100 mg/capsule) and samarium oxide (5 mg/capsule) as radioactive marker. Both 
formulations are filled into hard-shell capsules coated with a novel and patented colonic 
targeting coating system, which disintegrate upon arrival in the colon.  
Each formulation will be tested in 9 fasted, healthy volunteers, i.e. 18 subjects are recruited 
in total. Each subject receives one capsule by oral administration. The radiolabeling of the 
microparticles is based on neutron activation of the incorporated samarium oxide. In this 
process, the stable isotope Sm-152 contained in samarium oxide is converted to Sm-153, and 
the activated capsules are stored in radiation protection containers till administration. Before 
administration to the volunteers, the capsules are tested at the site of clinical investigation to 
ensure a radioactivity of ≤1 MBq, corresponding to 0.8 mSv (effective dose of radiation), 
which is considered to be harmless [235]. As a comparison, the annual radiation exposure of 
the average population in Switzerland is 3.2 mSv [236].  
On day 1 of the study, pre-dose PK sampling and pre-dose scintigraphy of the fasted subjects 
will be done before capsule intake to measure the baseline. After capsule intake (at 8:00), PK 
sampling and scintigraphy will be done at following time points (in hours): 1, 2, 3, 4, 4.5, 5, 
5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 24, 48 h post dose. The last sampling on 
day 1 is done at midnight (16 h post dose). The subjects can stay overnight or go home. On 
day 2 and day 3, there will be one sampling in the morning (24 h and 48 h post dose). On 
day 7, a follow-up investigation is done to finish the study. 
For determination of standard PK parameters, concentrations of metronidazole and its 
metabolites are analyzed in blood. Among others, following PK parameters will be 
determined: Maximum plasma concentration (Cmax); time to reach Cmax (Tmax); area under the 
concentration-time curve from dosing to 48 h post-dose (AUC0-t); elimination rate constant 
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(k); and lag time (Tlag) which is defined as the time (post-dose) of the last blood sample with 
a non-quantifiable metronidazole plasma concentration.  
Localization of initial capsule disintegration is mainly assessed by comparison of 
scintigraphy images (Tlag not only reflects the capsule disintegration and drug dissolution, but 
also hydrolysis of MBZ to metronidazole). The released granules are recognizable as a 
scintigraphic cloud, and their colonic residence time can be determined visually by 
comparison of a series of scintigraphy images taken over time after capsule rupture. In 
addition, gastric emptying time, small intestinal transit time, ileocecal junction residence 
time, and colonic arrival time are determined using the same method. Furthermore, the 
scintigraphic images will be quantitatively analyzed by dividing into two regions of interest 
(ROI), i.e. right side (ROI 1) and left side (ROI 2) as shown in Fig. 4.1. ROI 1 covers the 
ileocecal junction, ascending colon, and the right half of the transverse colon, whereas ROI 2 
covers the left half of the transverse colon, the descending colon, and the rectum. For each 
ROI, mean values of signal intensity from anterior and posterior images are calculated. The 
ratio of ROI 1 to ROI 2 will be used as quantitative parameter to compare colonic residence 
time from both formulations. For each time point, average ROI values of all nine subjects 
tested with mucoadhesive formulation can be calculated and compared to average ROI of the 
nine subjects tested with non-mucoadhesive formulation.  
 
Fig. 4.1: The two ROIs for quantitative analysis of scintigraphy images.  
R = right; L = left, ANT = anterior 
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5 Discussions 
The development of the presented multiparticulate and mucoadhesive formulation platform 
for colon delivery consisted of three steps. The different solvent-evaporation methods for 
drug loading into FCC and the underlying mechanisms are discussed in Chapter 5.1. 
Technical aspects of mucoadhesive coating and in vitro particle retention of microparticles 
are discussed in Chapter 5.2 and 5.3, respectively. The in vivo potential of mucoadhesive 
colon drug delivery systems is discussed in Chapter 5.4. The development of the colonic-
targeted capsule coating was carried out by Tillotts Pharma based on their patented 
technology and internal know-how and is not part of this thesis. 
5.1 Drug loading into FCC  
The novel pharmaceutical excipient FCC was demonstrated to be a feasible carrier material 
for various types of drugs, and drug loading was performed in a rotary evaporator [231], or a 
fluidized-bed process [237]. For both methods, the drug-loading mechanism is based on 
solvent evaporation and drug crystallization in the outer-porous domain of FCC. This is in 
contrast to immersion methods which are based on drug adsorption to the porous carriers 
[238–244], and which were often used for drug loading of mesoporous nanomaterials. The 
advantages of the presented solvent-evaporation methods are higher loading efficiencies and 
precise control of the loaded drug content.  
A drawback of the solvent-evaporation method is that loading efficiency (which has to be 
differentiated from the drug load) has to be determined qualitatively by SEM analysis, since 
non-loaded drug crystals cannot be separated from the drug-loaded particles to perform 
quantitative analysis of loading efficiency. Agglomerates are formed by drug crystals 
growing in the interparticle voids, and thus, agglomerates were also a sign of inefficient drug 
loading. Loading efficiencies of the tested drugs were excellent up to a drug load of 35-40%, 
which was defined as the drug-loading capacity. The excellent loading efficiencies can be 
explained by heterogeneous nucleation on the outer lamellas of FCC [245]. Heterogeneous 
nucleation is the formation of critical drug clusters (nuclei) on a pre-existing surface, which 
requires less energy in comparison to nucleation without pre-existing surfaces (homogeneous 
nucleation). Hence, the drug preferably crystallizes on the large lamellar surface of FCC. 
The high drug-loading capacities, up to 40% (w/w), were possible due the macroporous 
characteristics (0.05-1 µm pore size) of the outer stratum of FCC. Measurement of pore-size 
distribution by mercury intrusion revealed that most drug was deposited in the outer-porous 
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domain of FCC, and not in the mesoporous inner core. This was possibly due to higher 
crystallization pressures occurring in mesoporous systems [246]. The possibility to increase 
the drug-loading capacity by slowing down the evaporation process was exploited 
(decreasing the pressure by 50 mbar instead of 100 mbar per 0.5 hour), but no improvement 
of drug-loading efficiency could be achieved at high drug loads of 45% (results not shown). 
Hence, the drug was preferably crystallizing in the outer pores with diameters up to 1 µm 
[231]. Accordingly, drug-loading by solvent evaporation might not be suitable for 
mesoporous drug carriers, as the crystals preferably grow outside the particles [246]. 
Therefore, comparative studies with mesoporous microparticles, such as AEROPERL® or 
Neusilin US2, have not been carried out.  
Despite a deposition of mainly crystalline drug (not amorphous), drug dissolution rates were 
increased for MBZ- and nifedipine-loaded FCC in comparison to drug powder. This effect 
was explained by the increased surface area associated with the high porosity of FCC and its 
small particle size (5-15 µm). Therefore, drug loading into FCC presents an effective strategy 
for oral delivery of poorly water-soluble drugs. Based on these mechanistic investigations, 
further developments were carried out to improve the drug-loading method in terms of 
manufacturability and increased drug-release rates.  
The fluidized-bed process was evaluated for drug loading into FCC using MBZ as model 
drug for treatment of colonic diseases Preliminary trials with a drug load of 40% (w/w) 
showed excellent loading efficiency and similar pore-size distribution data as for particles 
obtained by the rotary-evaporation method. This is not surprising, as the mechanism of drug 
loading in the fluidized-bed process is very similar to the solvent-evaporation method using 
the rotary evaporator, meaning that drug crystallization occurs on the large surface area of the 
outer pores of FCC. The main difference is that drying is not based on reduced pressures, but 
on heat and moisture transfer by applying an air flow at elevated temperature. However, it 
was important to adjust the parameters as such that no spray drying effect occurred, i.e. that 
the spray solution did not dry before it got in contact with FCC particles. Limnell et al. [247] 
have already demonstrated the feasibility of the fluidized-bed process for drug loading of 
indomethacin into two different types of mesoporous silica. However, the advantage of FCC 
is the macroporous outer stratum allowing higher drug loads than for mesoporous materials.  
The fluidized-bed process offered the possibility of co-spraying solubility-enhancing 
polymers. In the performed drug-loading experiments, PVP K-25and PEG 3000 were used in 
a drug-to-polymer ratio of 50:50 (w/w). Based on SEM and XRPD analysis, it was found that 
the loaded drug was present in a crystalline state, embedded in the polymer matrix [237]. 
Stabilization of the drug in amorphous form is possible by increasing the amount of polymer, 
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and could be a strategy to increase the drug dissolution rate. However, this would reduce the 
drug loading capacity.  
Co-loading with hydrophilic polymers was also hypothesized to be useful to improve the 
homogeneity of the subsequent chitosan coating. MBZ-loaded FCC without co-loaded 
polymer has a hydrophobic surface due to the hydrophobicity of MBZ, and hence, a poor 
wettability of the spray solution is expected [248]. Hydrophilization of the particle surface by 
co-loading with PVP or PEG should lead to better wettability [249] of the chitosan spray 
solution on the particle surface. 
To improve the flowability of FCC, granulation by roller compaction could be performed 
prior to drug loading [228], provided that the macroporous characteristics of the outer 
stratum is not lost after granulation. Such a larger particle size of the FCC granules (e.g. 
around 100 µm) would also be beneficial for the subsequent chitosan-coating step to avoid 
further granulation, and to improve the reproducibility of the chitosan-coated particles in 
terms of particle size distribution and mucoadhesivity. It should be noted that the mean 
particle sizes (D50) of the three different chitosan-coating batches MMW-5, MMW-10, and 
LMW-5 were highly variable, i.e. 54.4 ± 2.0 μm, 183.5 ± 10.0 μm, and 190.9 ± 11.0 μm, 
respectively [237]. 
5.2 Mucoadhesive coating of microparticles 
For mucoadhesive coating of microparticles, a pH-dependent precipitation method [86] and a 
fluidized-bed method [237] were developed. In both methods, the semi-synthetic polymer 
chitosan was used for mucoadhesive coating. Chitosan is well known for its biodegradability, 
biocompatibility, and excellent mucoadhesivity. The relatively low viscosity of dilute 
chitosan solutions was an additional important property for the feasibility of the reported 
methods.  
The development of a precipitation method was possible due to the pH-dependent solubility 
of chitosan which is insoluble at pH >6. The method was modified from Han et al. [250] who 
prepared hollow chitosan capsules by repeated incubation of calcium carbonate particles in 
buffered chitosan solutions. For the preparation of the presented mucoadhesive 
microparticles, dissolution of the core particles was not desired, and the micrometer thick 
chitosan coating was obtained in one precipitation cycle. For titration of the chitosan 
solution, highly diluted NaOH was used (0.05 M) in order to prevent fast and locally 
increased precipitation. It can be assumed that chitosan precipitated directly on the surface of 
FCC particles due to heterogeneous nucleation [245] and the ionic interactions with calcium 
carbonate [250]. A critical step in the method was the initial suspension of the drug-loaded 
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FCC in the slightly acidic chitosan solution (pH 5), leading to partial decomposition of 
calcium carbonate and dissolution of MBZ. However, the amount of decomposed FCC 
during the whole precipitation process was only 3% (w/w) as measured by calcium-ion 
analysis of the remaining solution. The fraction of dissolved drug was calculated to be very 
similar (3.5%, w/w) based on the solubility of MBZ. Eventually, FCC, MBZ and chitosan 
contents were all close to the expected values. Nevertheless, for development of a delivery 
platform also applicable to water soluble drugs, alternative methods had to be evaluated to 
achieve reproducible mucoadhesive coatings on microparticles. 
Established pharmaceutical processes have been evaluated in preliminary trials, e.g. 
lyophilization and spray drying. However, only the fluidized-bed process was feasible for 
mucoadhesive coating of microparticles. The drug-loaded FCC particles were spray-coated 
with a chitosan solution. This approach had several advantages compared to the precipitation 
method, such as larger batch size, higher production yields, and better suitability for scale-up. 
Furthermore, the absence of a milling step was of great importance in terms of mucoadhesive 
performance since there was no destruction of the chitosan coating. As a consequence, a 
lower amount of chitosan coating was required compared to the precipitation method to 
obtain particles with similar mucoadhesivity. Regarding the manufacturability, low molecular 
weight (LMW) chitosan was superior to medium molecular weight (MMW) chitosan due to 
the reduced viscosity of the spray solution minimizing the risk of nozzle blocking. In the 
optimized formulation method, a higher spray rate was used (5 g/min vs. 1.5 g/min) to reduce 
the process time. However, it has to be mentioned that this high spray rate resulted in larger 
granules (D50 ≈ 190 µm), even though only 5% (w/w) of LMW chitosan was applied. Hence, 
the spray rate presents a critical process parameter that could be optimized to obtain smaller 
particles. 
In addition, the development of non-mucoadhesive microparticles with similar mean particle 
size was required as control in the in vitro flow-detachment experiments, and as comparison 
to the mucoadhesive microparticles in the planned in vivo gamma-scintigraphy studies. For 
this purpose, MBZ-loaded FCC was granulated with ethylcellulose in a fluidized-bed process 
by spraying an aqueous binder solution containing PVP K-25. The prepared control particles 
had a median particle size of 115.2 ± 3.5 µm, and practically no mucoadhesive interactions 
on colonic mucosa was measured (mean particle retention was 6.7% ± 8.4%, n=3). 
Therefore, these ethylcellulose particles are suited to be used as non-mucoadhesive control in 
the gamma-scintigraphy studies in humans. 
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5.3 Investigation of in vitro particle-retention 
For evaluation of mucoadhesive properties of prepared microparticles, a suitable in vitro 
mucoadhesion test was developed. To simulate the drag forces acting on the particles in the 
gastrointestinal tract, a flow-detachment method was preferred to the commonly used tensile-
detachment method. A flow-channel device with an improved design was built in-house, and 
marker-ion analysis (calcium) was applied for reliable quantification of microparticles [86].  
The development of the flow-channel device required several preliminary tests to evaluate 
the optimal channel geometry. In a closed channel with laminar flow regime, the flow 
velocity at the solid-fluid interface was too low to set the particles in motion, regardless of 
their mucoadhesive interactions. The problem observed in the semi-cylindrical channel was 
that the fluid formed a thin stream with an unreproducible (eddy) flow pattern. Therefore, the 
flat open channel was evaluated as the most suitable channel geometry. The use of multiple 
nozzles for inlet flow, as proposed by Batchelor et al. [76], was found to be an important 
feature to ensure homogeneous flow distribution throughout the channel area.  
A new feature of our design was the mucosa holder on the support plate, on which the 
mucosal tissue could be clamped with the fixation plate. To prevent excessive mucosa from 
squeezing into the channel, a void space surrounding the mucosa holder was necessary. The 
sealing was tight enough to prevent leakage of the flow medium. Furthermore, the mucosal 
tissue remained firmly attached to the support plate during the whole experiment without 
additional fixation aids such as pins [84] or low vacuum [88,94,251]. To simulate the 
targeted tissue of our formulations, porcine colonic mucosa was used as substrate in the 
particle-retention assay, as it shows similarities to the human colonic mucosa in terms of 
anatomy and mucin structure [252].  
Direct quantification of the inert carrier particle theoretically presents a more precise and 
reliable method compared to usual methods such as visual counting, which is limited to a 
certain particle size, and weighing of collected solids, which is biased by detached mucus and 
dissolved drug. The high sensitivity of the marker-ion analysis allowed for the first time 
precise characterization of mucoadhesive microparticles without additional labeling. 
However, the feasibility of using calcium ions as a marker to quantify the detached particles 
had to be evaluated first, since calcium ions are abundant in biological tissues. Indeed, 
control experiments without any microparticles showed relatively high amount of tissue-
derived calcium. However, validation of the marker-ion analysis by image analysis of 
detached particles retained on a black filter showed a different picture. The projected area of 
photographed particles was in good correlation with the calcium concentration measured by 
capillary electrophoresis. Hence, the influence of tissue-derived calcium flux was found to be 
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negligible when the mucosa was covered with FCC particles. Therefore, marker-ion analysis 
was routinely applied for particle quantification in collected fractions. The obtained results 
usually showed low standard deviations, and FCC recoveries close to 100%, indicating a 
good precision and accuracy of the method. As an alternative to capillary electrophoresis, 
other methods for quantification of calcium ions could be used, such as flame atomic 
absorption spectrometry or ion chromatography. The applicability of marker-ion analysis to 
other carrier materials such as silica or alumina has to be assessed individually. 
Investigation of two size fractions of microparticles (<90 µm and 125-250 µm) revealed a 
size-dependent in vitro retention behavior. It was shown that bigger particles were 
significantly better retained on mucosal tissue than the smaller ones, which was consistent for 
all four chitosan concentrations (0%, 9.1%, 16.7%, and 33.3%, w/w). This finding is 
contradictory to generally accepted mucoadhesion theories. Since this size-dependency was 
also observed for non-mucoadhesive control particles, additional retention mechanisms other 
than mucoadhesive interactions were involved. This can be explained by the forces acting on 
a particle in an open channel flow [86].  
To set a particle in motion, the resulting weight of the particle has to be exceeded by the drag 
force, which is exerted by the fluid onto the particle. However, the ratio of resulting weight to 
drag force increases exponentially with increasing particle size. Hence, bigger particles can 
resist better the washout, and control experiments with particles of similar size and density 
would be ideal for correct data interpretation. However, particles prepared in the fluidized-
bed had wide particle size distributions and varying median diameters (D50). Mucoadhesive 
microparticles coated with 5% of MMW chitosan (MMW-5, w/w) were the smallest 
(D50 ≈ 55 µm) and the ones coated with 5% of LMW chitosan (LMW-5, w/w) were the 
largest (D50 ≈ 190 µm), as measured by a Camsizer XT instrument. Since grinding would 
destroy the mucoadhesive coating, and size fractionation was not possible due to insufficient 
batch sizes, it was very difficult to prepare non-mucoadhesive control particles with similar 
D50 and size distribution. Therefore, the D50 of the non-mucoadhesive ethylcellulose control 
particles should be in between the MMW-5 and LMW-5 particles. This was well achieved 
since the control particles had a D50 of of 115 µm.  
All chitosan formulations prepared in the fluidized-bed showed significantly improved 
particle retention compared to the ethylcellulose control particles. The optimized 
mucoadhesive formulation coated with 5% LMW chitosan was selected as a prototype for the 
pharmaco-scintigraphy study in humans due to the good in vitro particle retention and 
manufacturability. 
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5.4 In vitro assessment of colonic mucoadhesion and in vivo considerations 
The particle-retention assay was a useful indicative tool to characterize and optimize the 
mucoadhesive microparticles in vitro during the development stage. To simulate the in vivo 
conditions in the human large intestine, fresh porcine colonic tissue was used and the 
particles were exposed to drag forces of a constant flow of fluid. However, many in vivo 
parameters are difficult to simulate in this standardized in vitro assay, such as pre-hydration 
and dispersion of the dosage form, motility of the colonic content, and turnover of the mucus 
gel layer. The mucoadhesive microparticles must overcome various hurdles to establish a 
successful bioadhesive contact with the colonic mucus layer as illustrated in Fig. 5.1. 
 
 
Fig. 5.1: The hurdles that a mucoadhesive and multiparticulate capsule formulation must 
overcome for optimal mucoadhesive performance in the colon. A) Dissolution of the capsule 
coating in the ileocolonic region, B) dispersion of the microparticles to improve the 
therapeutic effect, C) migration through the colonic content to reach the mucus layer, 
D) overhydration of the mucoadhesive microparticles and the mucus turnover eventually 
present limiting factors of mucoadhesion in the colon. 
 
Once the colonic-targeted capsule is dissolved or disintegrated at the desired site, i.e. in the 
ileocolonic region, the released mucoadhesive microparticles have to disperse and spread 
along the colonic wall. However, hydration and swelling of the mucoadhesive microparticles 
in the capsule can lead to agglomerates as observed in USP II and IV dissolution studies. 
When no dispersibility-enhancing excipient was used, the agglomerates remained in the 
shape of the dissolved capsule as shown in Fig. 4 of Chapter 3.3 [232]. A similar issue was 
observed by McGirr et al. [234] when they administered radiolabeled carbomers to beagle 
dogs. After remotely-controlled opening of the capsule (Intelisite®), only little dispersion of 
radioactivity was observed. Furthermore, the capsule recovered from the stool showed 
incomplete release of the polymer, probably due to hydration and swelling of the polymer 
inside the capsule before the polymer could be released. Therefore, we evaluated different 
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excipients to improve the dispersibility of mucoadhesive microparticles. In preliminary trials, 
hydrophilic fumed silica (colloidal silica) showed the most promising results and further 
investigations on dry-particle coating of mucoadhesive microparticles with colloidal silica 
were performed. The influence of silica concentrations on particle retention and dispersibility 
were of particular interest.  
In the study presented in Chapter 3.3 [232], it was found that colloidal silica can be added in 
concentrations up to 5% (w/w) without reducing the mucoadhesive properties in vitro. 
Indeed, a promising effect on particle dispersion was found by visual observation and also by 
increased dissolution rates of silica-coated particles. The latter can be explained by larger 
surface areas due to size reduction of the agglomerates, i.e. improved particle dispersion. At 
such high concentrations, silica nanoparticles were mainly present as secondary agglomerates 
with sizes ranging from 0.1-1 µm. These silica agglomerates were found to form an effective 
“shield” around the mucoadhesive particles, preventing a direct contact between the 
mucoadhesive surfaces. It is assumed that the silica monolayers, i.e. individual silica particles 
adsorbed to the chitosan surface, have a much lower dispersibility-enhancing effect than the 
silica agglomerates.  
Despite the promising results indicating a dispersibility-enhancing effect of silica, an in vitro 
- in vivo correlation is disputable. The higher viscosity of the colonic content compared to the 
in vitro test medium is clearly a factor which negatively affects the particle dispersion in 
vivo. On the other hand, the peristalsis of the colon, which is important for mixing and 
transporting of the colonic content, might lead to better particle dispersion than observed in 
vitro. Therefore, gamma-scintigraphy studies of radio-labelled mucoadhesive microparticles 
would be also relevant for the investigation of particle dispersion in the colon once rupture of 
the coating and the capsule shell  
For evaluation of in vitro particle retention on mucosal tissues, the microparticles were 
usually applied in dry state [68,90,91,253,254]. During a contact phase of 5 min [86], the 
particles had time for swelling, interpenetration into the mucin network, and formation of 
adhesive bonds. However, in reality the particles are hydrated before they can get in contact 
with the mucosal tissue, which already starts during dissolution of the capsule. Several 
tensile-detachment studies have shown that pre-hydration of mucoadhesive dosage forms 
leads to significantly reduced adhesive strength [255–257]. To measure particle retention of 
pre-hydrated particles, we used a special application method, and it was found that pre-
hydration of the optimized formulation (5% LMW chitosan) significantly reduced the particle 
retention from 55.4% ± 5.9% to 21.0% ± 9.2% (method and results of pre-hydration not 
published).  
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These findings were in agreement with the results of Albrecht et al. [258] who tested the 
influence of pre-hydration on retention of the microparticles in a flow channel. They showed 
that particle retention of dry particles was increased more than 2-fold compared to pre-
hydrated particles. They argued that dry polymeric particles show better interpenetration into 
the mucin network due to smaller sizes and increased surface area available for adhesive 
bonds in comparison to hydrated (swollen) particles. Other researchers explained the loss of 
mucoadhesive properties after pre-hydration by dissolution of the polymers and formation of 
a slippery mucilage [256,259]. Excessive accumulation of water molecules around the 
hydrophilic functional groups of mucoadhesive polymers also increases the diffusion path 
length, making it difficult for the polymer to get in close contact with the mucin molecule, 
and eventually reducing hydrogen bonding or ionic interactions.  
Therefore, a formulation system capable of delivering the mucoadhesive particles in a non-
hydrated state to the gastrointestinal mucosa would be of great benefit. In an interesting 
study, Albrecht et al. [260] proposed a special capsule device consisting of latex 
(impermeable to water), which is under tension and closed by a pH-sensitive twine made of 
Eudragit L100 55 (pH 5.5). When the twine is dissolved, relaxation of the stretched latex 
leads to immediate opening of the capsule, and the microparticles are released in dry state. In 
an in vivo study in rats, they demonstrated that mucoadhesive particles, which were delivered 
in non-hydrated state by such a latex capsule, had significantly prolonged residence time 
compared to hydrated particles delivered in a standard capsule. However, manufacturing of 
such a complex capsule device is very challenging at an industrial scale.  
The flow rate in the particle-retention assay was chosen much higher than expected in the 
colon to simulate harsher conditions. The purpose was to trigger a forced detachment of the 
mucoadhesive microparticles and to measure their resistance to the washout in a short time. 
Therefore, a fast flow of water was applied to simulate the drag forces acting on the particles. 
The parameters influencing the drag force are the speed and density of the flow medium, and 
the projected surface area exposed to the flow (see Eq. 4 in Chapter 3.2) The in vitro flow 
rate of 20 ml/min was much higher than the in vivo flow rate of approximately 1 ml/min to 
increase the height of the stream and ensure a full immersion of the particles. The speed of 
flow applied by the inlet nozzles was already high due to the small nozzle orifice diameter 
and the high flow rate. The average speed of flow along the channel (positioned at an angle 
of 45°) was approximately 50 mm/s as measured by the time until the initial water front 
arrived at the end of the channel. Hence, it can be assumed that the flow conditions in the 
colon are milder as simulated in the particle-retention assay and that mucoadhesive 
microparticles with good in vitro particle retention might increase the residence time in vivo, 
despite the negative influence of other factors such as pre-hydration or mucus turnover.  
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Assuming that the mucoadhesive particles can reach the intestinal wall and form a strong 
adhesive bond with the mucus layer, the retention is limited to a certain time since the mucus 
layer is constantly being renewed. Therefore, the mucus turnover rate is the time-limiting 
factor of particle retention (see Fig. 5.1). As an indication of colonic mucus turnover rate in 
humans, rat experiments have been performed, showing a colonic mucus turnover rate of 
around five hours [29]. In case of diarrhea, when the gastrointestinal transit time is 
significantly reduced, a transit time prolongation of five hours would be of clinical 
importance. However, in such a condition the mucus might be washed away quicker and it is 
very likely that shedding of the loose outer mucus layer already leads to particle detachment. 
Hence, the time of adhesion might be much less than the five hours required for complete 
renewal. Another factor to consider is the change of mucus integrity in a diseased state. For 
example, patients with ulcerative colitis were found to have a depletion of goblet cells and a 
lower rate of mucus secretion [261], i.e. the effect of mucoadhesion could be more 
pronounced in ulcerative colitis patients than in healthy humans due to a lower rate of mucus 
turnover. However, there is no data in literature clearly showing the influence of the mucus 
condition in diseased state on mucoadhesive potential. 
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6 Conclusions and outlook 
The focus in this work was the development of a multiparticulate formulation based on FCC 
microparticles. In this chapter, the successful development of the mucoadhesive and 
multiparticulate drug delivery system is summarized, and an outlook is given on other 
possible applications of FCC as oral drug carrier.  
The formulation concept proposed in Chapter 2 (Aims) was successfully achieved. Porous 
FCC microparticles were used as drug carriers, and the fluidized-bed process was suitable for 
drug loading and mucoadhesive coating. The antibiotic MBZ was used as model drug for 
local treatment of colonic diseases (Chlostridium difficile infections). The use of LMW 
chitosan spray solutions reduced the risk of nozzle blocking compared to MMW chitosan, 
improving the manufacturability of the mucoadhesive microparticles. The optimized 
formulations had a high drug load, and showed good in vitro particle retention on porcine 
colonic mucosa.  
By using FCC as the drug carrier, various types and high amounts of drug can be loaded into 
the porous calcium carbonate skeleton. Both presented drug-loading methods, i.e. the rotary-
evaporation and fluidized-bed method, were based on the principle of solvent evaporation 
and crystallization. The rationale of using porous drug carriers for preparation of 
mucoadhesive microparticles is to have a stable skeleton for loading the drug and for further 
functionalization with a mucoadhesive coating which remains intact until the drug is 
released. Furthermore, the spherical shape of porous carrier particles should improve the 
coating quality compared to non-spherical particles, such as micronized drug crystals, which 
are usually characterized by poor flowability and higher agglomeration tendency during 
fluidized-bed coating.  
For evaluation of the mucoadhesive properties of the chitosan-coated microparticles, a 
particle-retention assay was developed featuring a novel and reliable method for particle 
quantification (marker-ion analysis), and a modified flow-channel design for easier clamping 
of the mucosal tissue.  
To prevent agglomeration of mucoadhesive microparticles due to swelling in the capsule, 
dry-particle coating with hydrophilic fumed silica was investigated. Promising results were 
obtained by visual observation and dissolution studies, indicating a dispersibility-enhancing 
effect of silica. Importantly, mucoadhesion was not negatively influenced by silica up to a 
concentration of 5% (w/w).  
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The application dossier of the pharmaco-scintigraphy study was approved by Swissmedic and 
the Ethics committee. The clinical batches were manufactured by Tillotts Pharma AG under 
GMP conditions, and the pharmaco-scintigraphy will be carried out at the University 
Hospital Basel. The results of the study is of great relevance, as it is the first-in-human 
investigation (from the best of our knowledge) of mucoadhesive microparticles delivered to 
the colon. A positive outcome, i.e. a prolonged residence time of mucoadhesive 
microparticles in the colon compared to the non-mucoadhesive control particles, would be an 
indication that the drug delivey strategy of mucoadhesion could also be applied to the harsh 
conditions in the large intestine, and that further research in this field would be promising. 
Since the preparation method allows exchange of the drug without affecting the 
manufacturability and mucoadhesivity of the outer chitosan layer, this formulation platform 
has great potential for local treatment of other colonic diseases. The presented formulation 
concept was subject to a patent application [262]. 
Drug-loaded FCC could also be used for other applications in oral drug delivery, such as 
immediate release formulations, orally dispersible tablets (ODTs), and as carrier of highly 
potent substances requiring low and precise dosing. Since the drug-loading approach was 
shown to result in enhanced drug dissolution, drug-loaded FCC might be beneficial for the 
development of immediate release formulations, in particular for poorly water-soluble drugs. 
The good compaction properties of FCC have already been demonstrated by Stirnimann et al. 
[228]. However, the use of a superdisintegrant would be essential to promote immediate 
disintegration into smaller particles, providing a large surface area for fast and complete drug 
dissolution. For better manufacturability of such tablets, granulation of drug-loaded FCC and 
superdisintegrants can be performed by roller compaction. It was shown that roller 
compaction of FCC had little impact on the compactibility of the obtained granules. The 
suitability of FCC for development of orally dispersible tablets (ODTs) has recently been 
reported [227]. Drug loading into FCC prior to roller compaction could be a promising 
strategy to prevent segregation of drug and excipients during manufacturing. Furthermore, 
improved dissolution of poorly water-soluble drugs in the saliva could lead to a large fraction 
of drug absorbed via the buccal mucosa, and hence, leading to a rapid onset of the 
pharmacological effect.  
The use of FCC as a drug carrier is also encouraged for formulation of drugs with a narrow 
therapeutic window requiring low and precise dosing, since drug loading into FCC leads to a 
uniform drug distribution, even at very low drug loads. Since no segregation of drug and 
excipients can occur, an increased uniformity of drug content is expected. However, the 
usefulness of drug-loaded FCC for tablet formulations has not been investigated thus far, and 
further research is required to exploit the full potential of FCC as an oral drug carrier.
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